CONTROL BIONICS LIMITED — Interim / Quarterly Report 2026

Feb 25, 2026

==> picture [298 x 91] intentionally omitted <==

Business Update February 2026

==> picture [204 x 28] intentionally omitted <==

----- Start of picture text -----

Jeremy Steele
----- End of picture text -----

==> picture [710 x 810] intentionally omitted <==

HY26 Financial Overview

HY26 Investor Update | February 2026

$2.8M $5.3M $3.1M Revenue Capital Raised during the half, Closing cash balance Broadly consistent with the strengthening liquidity 31 December 2025

Closing cash balance 31 December 2025

Revenue Broadly consistent with the prior period, delivered with a leaner sales structure

==> picture [349 x 386] intentionally omitted <==

• Key strategic milestones achieved during the half, including completion of the NEA acquisition and announcement of Apple BCI collaboration

• Selling expenses reduced during the half, reflecting disciplined cost management

• Net loss of $3.6m, reflecting continued investment in platform development and market expansion, and one-off non-cash acquisition impacts associated with the acquisition of the remaining interest in Neuro Elite Athletics (NEA)

NeuroNode Distributor Strategy

HY26 Investor Update | February 2026

Recent Progress

• Two NN-only distribution agreements executed in the US

• Tobii Dynavox: initial six-month pilot across five US states with confidence this will expand USwide

• PRC-Saltillo: formal distribution agreement in place

==> picture [209 x 155] intentionally omitted <==

What this Demonstrates

• Independent demand for NeuroNode as a standalone access

• solution

• Validation from leading global AAC partners

• Lower execution risk through a distributor-led model

• Higher gross margin, volume-based sales

NeuroStrip Market Engagement

HY26 Investor Update | February 2026

==> picture [364 x 245] intentionally omitted <==

==> picture [414 x 252] intentionally omitted <==

==> picture [374 x 261] intentionally omitted <==

NeuroStrip is in-market and being used across multiple settings

Applications span healthcare, performance, and institutional environments

Engagement is being driven by real-world use and outcomes

==> picture [1440 x 148] intentionally omitted <==

Next Level: Capital-Light Scale Opportunity

HY26 Investor Update | February 2026

• Strategic partnership with NextLevel Assistive Technology to commercialise iOS-based speechgenerating devices in the US

• Capital-light model, with NextLevel funding device tooling and manufacturing

• Complements NeuroNode by expanding access to a higher-volume AAC segment through existing distributor channels

• Opportunity to participate in scale while maintaining focus on core neural-interface technology

• Currently in negotiations for non-binding LOIs with distributors for >1,000 devices per year. Distributors would typically be funded between US$6,000-7,5000 / device.

• CBL management estimate the potential addressable market for iOS touch devices in the US to be more than 5,000 devices annually.

Strategic Repositioning

==> picture [580 x 338] intentionally omitted <==

HY26 Investor Update | February 2026

• Strategic repositioning is nearing completion

• Focused on clearer articulation of priorities across NeuroNode, NeuroStrip, and platform opportunities

• Intended to better reflect CBL’s evolving commercial model and growth pathways

• Shareholder update planned toward the end of March

Disclaimer

HY26 Investor Update | February 2026

This presentation is intended to provide a general outline only and is not intended to be a definitive statement on the subject matter covered in it. The information in this presentation, whether written or verbal, has been prepared without taking into account the commercial, financial or other needs of any individual or organisation.

Certain information may relate to protected intellectual property rights owned by Control Bionics Limited (Control Bionics) and its subsidiaries (together the Group).

While due care has been taken in compiling the information based on the information available to Control Bionics at the date of the presentation material, neither Control Bionics nor its officers or advisors or any other person warrants the accuracy, reliability, completeness or timeliness of the information or guarantees the commercial or investment performance of the Group.

The information does not constitute advice of any kind and should not be relied upon as such. Investors must make their own independent assessment of the Group and undertake such additional enquiries as they deem necessary or appropriate for the own investment purposes. Any and all use of the information is at your own risk.

No representations, warranty or assurance (express or implied) is given or made in relation to any forward looking statement by and person (including Control Bionics). In particular, no representation ,warranty or assurance (express or implied) is given in relation to any underlying assumptions or that any forward looking statement will be achieved. Actual future events may vary materially from the forward looking statements and the assumptions on which the forward looking statements are based.

Subject to any continuing obligations under applicable law or any relevant listing rules of the Australian Securities Exchange, Control Bionics disclaims any obligation or undertaking to disseminate any updates or revisions to any forward looking statements in these materials to reflect any change in expectations to any forward looking statements or any change in events, conditions or circumstances on which and such statement is based. Nothing in these materials shall under any circumstances create an implication that there has be been no change in the affairs of the Group since the date of these materials.

Contact Details

HY26 Investor Update | February 2026

==> picture [467 x 311] intentionally omitted <==

CEO and Managing Director Jeremy Steele

jsteele@controlbionics.com AUS: +61 433 229 470 US: +1 (855) 831-7521 www.controlbionics.com

==> picture [1440 x 190] intentionally omitted <==